The relationship of molecular genetic to clinical diagnosis of familial hypercholesterolemia in a Danish population.

The genes encoding the LDL receptor and apoB were screened for mutations associated with familial hypercholesterolemia (FH) in 408 patients referred to the Lipid Clinic in 1995-2003. The study aimed at testing the ability of three different sets of clinical criteria to predict the results of molecular genetic analysis, and secondly test whether population-based age- and sex-specific percentiles of LDL-cholesterol offer useful supplemental information in the selection of patients for molecular genetic analysis. The patients were retrospectively categorised according to Simon Broome Register Group criteria, Make Early Diagnosis to Prevent Early Death criteria (MEDPED) and the Dutch Lipid Clinic Network criteria, and the distribution of patients was compared to the results of the molecular genetic analysis. The study illustrates a classical dilemma. Mutation detection rates (and specificities) are high only if sensitivity is very low and vice versa: to find most mutation carriers, even patients with only possible FH must be examined by molecular genetic testing leading to mutation detection rates as low as 30-40%.

[1]  T. Miettinen,et al.  Diagnosis of heterozygous familial hypercholesterolemia. DNA analysis complements clinical examination and analysis of serum lipid levels. , 1992, Arteriosclerosis and thrombosis : a journal of vascular biology.

[2]  R. Levy,et al.  Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge. , 1972, Clinical chemistry.

[3]  S. Humphries,et al.  Comparison of the risk of fatal coronary heart disease in treated xanthomatous and non-xanthomatous heterozygous familial hypercholesterolaemia: a prospective registry study. , 2003, Atherosclerosis.

[4]  S. Humphries,et al.  A review on the diagnosis, natural history, and treatment of familial hypercholesterolaemia. , 2003, Atherosclerosis.

[5]  M. Brown,et al.  Familial hypercholesterolemia: identification of a defect in the regulation of 3-hydroxy-3-methylglutaryl coenzyme A reductase activity associated with overproduction of cholesterol. , 1973, Proceedings of the National Academy of Sciences of the United States of America.

[6]  J. Kastelein,et al.  The molecular basis of familial hypercholesterolemia in The Netherlands , 2001, Human Genetics.

[7]  Jonathan D. Cohen,et al.  Monogenic hypercholesterolemia: new insights in pathogenesis and treatment. , 2003, The Journal of clinical investigation.

[8]  I. Young,et al.  A novel single base deletion in the LDLR gene (211delG): Effect on serum lipid profiles and the influence of other genetic polymorphisms in the ACE, APOE and APOB genes. , 1996, Atherosclerosis.

[9]  H. Jensen,et al.  The molecular genetic basis and diagnosis of familial hypercholesterolemia in Denmark. , 2002, Danish medical bulletin.

[10]  M. Leppert,et al.  Diagnosing heterozygous familial hypercholesterolemia using new practical criteria validated by molecular genetics. , 1993, The American journal of cardiology.

[11]  R. Westendorp,et al.  Additional risk factors influence excess mortality in heterozygous familial hypercholesterolaemia. , 2000, Atherosclerosis.

[12]  O. Faergeman,et al.  High sensitivity of the single-strand conformation polymorphism method for detecting sequence variations in the low-density lipoprotein receptor gene validated by DNA sequencing. , 1996, Clinical chemistry.

[13]  S. Humphries,et al.  Genetic testing for familial hypercholesterolaemia: practical and ethical issues. , 1997, QJM : monthly journal of the Association of Physicians.

[14]  R. Krauss,et al.  Familial defective apolipoprotein B-100: a mutation of apolipoprotein B that causes hypercholesterolemia. , 1990, Journal of lipid research.

[15]  L. Bolund,et al.  Normolipidemia and hypercholesterolemia in persons heterozygous for the same 1592+5G→A splice site mutation in the low‐density lipoprotein receptor gene , 1999, Clinical genetics.

[16]  M. Skolnick,et al.  A mutation in PCSK9 causing autosomal-dominant hypercholesterolemia in a Utah pedigree , 2004, Human Genetics.

[17]  G. Coetzee,et al.  Characterization of six patients who are double heterozygotes for familial hypercholesterolemia and familial defective apo B-100. , 1993, Arteriosclerosis and thrombosis : a journal of vascular biology.

[18]  J. Kastelein,et al.  Results from a family and DNA based active identification programme for familial hypercholesterolaemia , 2001, Journal of epidemiology and community health.

[19]  E. Sijbrands,et al.  Review of first 5 years of screening for familial hypercholesterolaemia in the Netherlands , 2001, The Lancet.

[20]  D. Zwijnenburg,et al.  Relative quantification of 40 nucleic acid sequences by multiplex ligation-dependent probe amplification. , 2002, Nucleic acids research.

[21]  J. Weissenbach,et al.  Mutations in PCSK9 cause autosomal dominant hypercholesterolemia , 2003, Nature Genetics.

[22]  D. Blankenhorn,et al.  The inheritance of familial hypercholesterolemia. , 1972, The American journal of medicine.

[23]  O. Faergeman,et al.  Spectrum of LDL receptor gene mutations in Denmark: implications for molecular diagnostic strategy in heterozygous familial hypercholesterolemia. , 1999, Atherosclerosis.

[24]  O. Faergeman,et al.  Detection of the apoB-3500 mutation (glutamine for arginine) by gene amplification and cleavage with MspI. , 1991, Journal of lipid research.

[25]  S. Humphries,et al.  A molecular genetic service for diagnosing individuals with familial hypercholesterolaemia (FH) in the United Kingdom , 2001, European Journal of Human Genetics.